61. 自己免疫性溶血性貧血 [臨床試験数:90,薬物数:72(DrugBank:23),標的遺伝子数:19,標的パスウェイ数:147

Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR19000234762019-07-012019-05-30Multicenter, prospective and open clinical study for rapamycin in the treatment of autoimmune hemolytic anemiaMulticenter, prospective and open clinical study for rapamycin in the treatment of autoimmune hemolytic anemia Autoimmune1:glucocorticoid;2:glucocorticoid & Ciclosporin;3:glucocorticoid & rapamycin;4:rapamycin;Tianjin Medical University General HospitalNULLPendingBoth1:20;2:20;3:20;4:20;China
2EUCTR2007-001377-28-PT09/01/200925/08/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
3EUCTR2007-001377-28-DE01/09/200815/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
4EUCTR2007-001377-28-NL15/07/200829/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
5EUCTR2007-001377-28-AT26/06/200827/05/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLNot RecruitingFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2007-001377-28-FR11/06/200829/02/2008Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAILPhase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously,-- AND who developed adverse events (AEs) corresponding to pre-specified newlydiagnosed autoimmune disorders OR who developed severe thrombocytopenia.
MedDRA version: 9.1Level: LLTClassification code 10061664Term: Autoimmune disorder
MedDRA version: 9.1Level: LLTClassification code 10025139Term: Lupus erythematosus systemic
MedDRA version: 9.1Level: LLTClassification code 10047888Term: Wegener's granulomatosis
MedDRA version: 9.1Level: LLTClassification code 10002817Term: Antiphospholipid syndrome
MedDRA version: 9.1Level: LLTClassification code 10040767Term: Sjogren's syndrome
MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
MedDRA version: 9.1Level: LLTClassification code 10028245Term: Multiple sclerosis
MedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitus
MedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's disease
MedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative
MedDRA version: 9.1Level: LLTClassification code 10003827Term: Autoimmune hepatitis
MedDRA version: 9.1Level: LLTClassification code 10049046Term: Autoimmune thyroiditis
MedDRA version: 9.1Level: LLTClassification code 10003822Term: Autoimmune haemolytic anaemia NOS
MedDRA version: 9.1Level: LLTClassification code 10034697Term: Pernicious anemia
MedDRA version: 9.1Level: LLTClassification code 10028417Term: Myasthenia gravis
MedDRA version: 9.1Level: LLTClassification code 10018620Term: Goodpasture's syndrome
MedDRA version: 9.1Level: LLTClassification code 10
Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection
INN or Proposed INN: Efalizumab
Other descriptive name: EFALIZUMAB
Merck Serono International S.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
92Phase 4Portugal;Germany;Netherlands;France;Austria